Shares of Mineralys Therapeutics, Inc. (MLYS) declined after the company announced a royalty buyout transaction alongside significant new debt and equity financing.
The stock is currently trading at $24.79, down $4.07 or 14.09%, on the Nasdaq. It opened at $26.48 after closing the previous session at $28.85. The stock has traded between $12.59 and $47.65 over the past 52 weeks.
Mineralys agreed to repurchase all future royalty obligations related to lorundrostat from Tanabe Pharma Corporation for $200 million upfront and up to $100 million in future commercial milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.